It has been designed to continuously prompt a
patient until notification is received that the appropriate action has been
taken. The Company anticipates its free cash flow(a) for
the year will be between $70 million and $80 million. Actual results and events may differ significantly from those
expressed or anticipated as a result of risks and uncertainties which
include, but are not limited to, the following: pricing pressures, the
success of the Company 's ongoing efforts to reduce costs, increasing
raw material costs, the consolidations of health care customers and
competitors, government reimbursement issues (including those that
affect the sales of and margins on product, along with the viability
of customers) both at the federal and state level , the ability to
design, manufacture, distribute and achieve market acceptance of new
products with higher functionality and lower costs, the effect of
offering customers competitive financing terms, Invacare's ability to
successfully identify, acquire and integrate strategic acquisition
candidates , the difficulties in managing and operating businesses in
many different foreign jurisdictions (including the recent Domus
acquisition), the timely completion of facility consolidations, the
vagaries of any litigation or regulatory investigations that the
Company may be or become involved in at any time (including the
previously-disclosed litigation with Respironics), the difficulties in
acquiring and maintaining a proprietary intellectual property
ownership position, the overall economic, market and industry growth
conditions (including the impact that acts of terrorism may have on
such growth conditions), foreign currency and interest rate risks,
Invacare's ability to improve financing terms and reduce working
capital, as well as the risks described from time to time in
Invacare's reports as filed with the Securities and Exchange
Commission. Gains will reflect the effectiveness of
thiazolidinedione oral anti-diabetic agents (TZDs) and combinations in
controlling hyperglycemia and preventing long -term complications of Type 2
diabetes.

concentrators bidet

Plans are already being formalized for larger production runs with expected
delivery before year end.

ALR Technologies' Medication
Reminders have already demonstrated a 97% improvement in patients
taking prescribed doses, in a study conducted by Columbia University. An average annual cost savings of $3,400
per diabetes was achieved for patients using a compliance reminder system
compared to the control population.

Business Editors

ELYRIA, Ohio----Invacare
Corporation (NYSE:IVC) today announced that its financial results for
the first quarter ended March 31, 2005 were in range with previous
guidance.
SG+A expense as a percentage of net sales increased by 0. Days sales
outstanding improved by four days compared to March 31, 2004, however
the negative impacts described above led Invacare to use $12 million
of free cash flow(a). Invacare Supply Group (ISG)
sales increased 7%, continuing ISG's consistent growth pattern over
the recent past.9, down from 5.53 and
$0. These and other trends are presented in Diabetes
Monitoring Products & Therapies, a new study from The Freedonia Group,
Inc. The introduction of new peptide agonists and non-TZD PPARs
(peroxisome proliferator-activated receptors) for a broader range of
metabolic targets (i.

colostomy holdaway

Operating income, which grew in total and as a percent of sales , was
more than offset by higher interest expense, primarily due to
acquisitions.8 at the end of last year
due to the factors previously discussed. The
expansion of patient education programs and promotion of preventive
medicine activities by the American Diabetes Association and other medical
groups will encourage more diabetic individuals to follow established
guidelines for self-testing and periodic professional examinations.

dme uvb

4 million last year in large part
due to lower sales of microprocessor controllers related to weakness
in the consumer power wheelchair market and due to costs related to
establishing the Company's sales and support infrastructure in Asia. Both factories in China are expected to contribute to
profits throughout the remainder of the year," said Mixon. The transition to increased Chinese
manufacturing with local sourcing is on track and should contribute
consistent with previous guidance.42 $0.

The information by segment is as follows:

Three Months Ended
March 31,
(In thousands) 2005 2004
----------------------------------------------------------------------
Revenues from external customers
North America $250,940 $237,283
Europe 102,091 69,338
Asia/Pacific 17,913 14,722
----------- ----------
Consolidated $370,944 $321,343
=========== ==========

Earnings (loss) before income taxes
North America $19,405 $21,871
Europe 3,882 1,140
Asia/Pacific (1,704) 437
All Other (1,693) (2,407)
----------- ----------
Consolidated $19 ,890 $21,041
=========== ==========

All Other consists of the domestic export unit, unallocated corporate
selling, general and administrative expense, the Invacare captive
insurance unit and inter-company profits, which do not meet the
quantitative criteria for determining reportable segments. Management believes that this financial measure provides
meaningful information for evaluating the overall financial
performance of the Company and its ability to repay debt or make
future investments (including acquisitions, etc. Products
which provide performance advantages over competitive offerings in blood
glucose monitoring, drug delivery or pharmacological actions will offer the
best opportunities.

urologicals ridden

alrt.5 percentage points compared to last year's first
quarter.9 million last year, largely due to continued
weakness in the rehab products line and the pricing reductions in the
standard products line.

EUROPE

For the quarter, European net sales increased 47% to $102. Foreign currency accounted for
six percentage points of the net sales increase, while acquisitions
contributed an additional forty percentage points for the quarter.9 million versus $1.
Commenting on the Company's anticipated results, Mixon said ,
"Although disappointed with the cash flow performance of some
divisions in the first quarter , the Company has made progress on two
critical strategic goals. We undertake no obligation to review or update these
forward-looking statements or other information contained herein.

INVACARE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED)

Three Months Ended
March 31,
(In thousands, except per share data) 2005 2004
----------------------------------------------------------------------
Net sales $370,944 $321,343
Cost of products sold 261,100 227,964
-- --------- ----------
Gross profit 109,844 93,379
Selling , general and administrative expense 83,962 71,238
----------- ----------
Operating income 25,882 22,141
Interest expense - net 5,992 1,100
----------- ----------
Earnings before income taxes 19,890 21,041
Income taxes 6,345 6,840
----------- ----------
Net earnings $13,545 $14,201
=========== ==========

Net earnings per share - basic $0.

nebulizer ostomy

com/PC500/index.

Invacare Corporation Reports Earnings in Range with Guidance

3 million last year.
"Invacare's first factory in China turned profitable at
quarter-end. Finally, Invacare is building its Asian sales and
support infrastructure and expects to begin seeing positive results in
the months ahead as we seek to build the market to $100 million over
the next five years. We are committed to increasing shareholder value
and believe Invacare, despite the difficult reimbursement environment,
can continue to earn strong returns for its shareholders.

urologicals nebulizer

PRESS RELEASE ALR Technologies' Disease Management Solutions Presents Opportunity to Significantly Lower Healthcare Costs of Patients with Chronic Diseases

(OTC BB: ALRT) is
pleased to announce that it has completed the development of its
next-generation medication and treatment compliance reminder system, the
ALRT500 and has scheduled a small-scale first production run to be
delivered in the third quarter of 2006. Foreign
currency accounted for two percentage points of the net sales
increase, while acquisitions contributed an additional ten percentage
points for the quarter. During the first quarter, cost reduction projects were ahead
of schedule in most manufacturing and sourcing locations. Malachi Mixon, III, chairman and chief executive officer,
stated, "We are pleased to report that Invacare achieved its guidance
in the first quarter for both sales and earnings . Sales of the rehab products line
decreased 7%, excluding acquisitions, due primarily to continued
Medicare eligibility pressures and Medicaid related reimbursement
pressures.7 million last year . Days sales outstanding were 66
days, improving by four days compared with the first quarter of last
year. Excluding the impact of
foreign currency and acquisitions, the net sales increase would be
between 5% and 7%. The three reportable segments represent operating
groups, which offer products to different geographic regions.

INVACARE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, March 31,
(In thousands) 2005 December 31, 2004
(unaudited) 2004 (unaudited)
-------------------------- --------------------------------------------
Current Assets
Cash, cash equivalents and
marketable securities $17,037 $32,766 $4,683
Trade receivables - net 282,801 287,950 263,033
Inventories - net 183,585 175,883 131 ,522
Deferred income taxes and other
current assets 68,472 68,552 65,630
Total current assets 551,895 565,151 464,868

Other Assets 149,762 153,846 78,713
Plant and equipment - net 191 ,972 191,163 154,641
Goodwill - net 723,571 717,964 442,229
Total assets $1,617,200 $1,628,124 $1,140,451
=========== =========== ===========

Liabilities and Shareholders'
Equity
Current Liabilities
Accounts payable $130,928 $149,413 $121,863
Accrued expenses 85,332 98,850 85,296
Accrued income taxes 6,999 7,816 21,458
Current maturities 1,746 2,062 2,163
----------- ----------- -----------
Total current liabilities 225,005 258,141 230,780

Long-term debt 552,990 547 ,974 232,398
Other long-term obligations 74,285 68,571 36,530

Shareholders ' equity 764,920 753,438 640,743
Total liabilities and
shareholders ' equity $1,617,200 $1,628,124 $1,140,451
=========== =========== ===========

INVACARE CORPORATION AND SUBSIDIARIES
RECONCILIATION FROM NET CASH PROVIDED (USED) BY
OPERATING ACTIVITIES TO FREE CASH FLOW (UNAUDITED)

Three Months Ended
March 31,
(In thousands) 2005 2004
----------------------------------------------------------------- -----
Net cash provided (used) by operating activities $(3,495) $30,284
Less:
Purchases of property and equipment - net (8,907) (8,355)
----------------------
Free Cash Flow $(12,402) $21,929
======================

Free cash flow is a non-GAAP financial measure that is comprised of
net cash provided (used) by operating activities less purchases of
property and equipment net of proceeds from sales of property and
equipment .

US demand for diabetes monitoring products
and therapies will increase 9. Among insulin
delivery devices, prefilled disposable pen injectors will see the fastest
gains in demand, based on infection prevention and convenience advantages.

incontinent concentrators

Additionally, European performance, excluding Domus, was weaker
than expected in the first quarter.

ostomy urostomy

3 million for the first quarter last year. Invacare Continuing Care Group (ICCG) sales increased
by 22% for the quarter, with acquisitions accounting for 15% of the
increase. The German decline was due to significant reimbursement
challenges for the Invacare wheelchair product lines.9
million versus $14. In terms of
Medicaid, numerous states , including California, Ohio and New York,
are challenging reimbursement on durable medical equipment
submissions, leading to slower payments and approvals for lower-priced
product, in addition to no reimbursement at all in some cases.6 billion in 2008,
benefitting from an increasing number of patients as well as trends
favoring the use of aggressive management and treatment regimens.

colostomy crutches

SG+A expense
increased 18% over last year's first quarter primarily due to
acquisitions and foreign currency translation. Equally important,
all geographical segments of the business have returned to sales
growth in the first quarter. Foreign currency accounted for
six percentage points of the net sales increase, while acquisitions
contributed an additional thirteen percentage points for the quarter.7 million versus earnings of $0. Excluding the impact of foreign
currency and acquisitions , the net sales increase is expected to be
between 6% and 8%. Rapid-acting formulations for post -prandial hyperglycemia management
and long-acting formulations for continuous basal control will provide the
best growth opportunities among insulin formulations.

Demand for oral anti-diabetic agents for Type 2 conditions will increase
over ten percent through 2008.

ridden nebulizer

ALR Technologies , Inc.

ALR Technologies, which specializes in health and disease management
products and services , has designed and manufactures medication compliance products
and compliance home-monitoring and intervention systems to meet the needs
for several targeted user groups.5 million versus $14.

FINANCIAL CONDITION

At the end of the first quarter, total debt outstanding was $554.0%, slightly
lower than the ratio at the end of last year.80. This is consistent with current analyst's
estimates but at the lower end of Invacare's previous guidance.46
=========== ==========
Weighted average shares outstanding - basic 31,359 31,094
=========== ==========

Net earnings per share - assuming dilution $0.
External insulin pumps will also post strong advances due to dosing
efficacy advantages.

lumbar nebulizer

The company is expected to generate approximately
$900,000 in twelve month revenue from the volume of this first production
run alone.

About the ALRT500

The ALRT500 is a medication and treatment reminder system that prompts a
person to take the necessary
treatments , medications or other health related actions in addition to
the appropriate dosage with caregiver instructions at the
appropriate time(s) of day.5
percentage points compared to first quarter last year.
A. In particular, reimbursement
issues in Germany led to lower sales of wheelchair products ., a Cleveland-based industrial market research firm.4 billion in 2008.e.

lancets ileostomy

alrt. Foreign currency
accounted for two percentage points of the increase in SG+A expense,
while acquisitions contributed an additional fifteen percentage
points.1
million versus $69.3 million last year. During
the quarter, the company has taken action to convert in the future
$150 million of floating rate exposure, where at quarter end 100% of
outstanding debt is floating rate.60 and $2.invacare.com
This press release contains forward-looking statements within the
meaning of the "Safe Harbor" provisions of the Private Securities
Litigation Reform Act of 1995.
Intersegment revenue for reportable segments was $22 ,758,000 for the
three months ended March 31, 2005 and $19,343,000 for the same period
a year ago .

colostomy commode

This release contains certain "forward-looking statements" relating to ALR
Tech's business , and these statements reflect the current views of ALR Tech
with respect to future events and are subject to certain risks,
uncertainties and assumptions. When used, the words "estimate," "expect ,"
"anticipate," "believe" and similar expressions are intended to identify
such forward-looking statements.

CONSOLIDATED RESULTS

Earnings per share for the quarter decreased 5% to $0 .
For the quarter, earnings before income taxes decreased 11% to
$19. The
1% sales increase for the quarter, excluding foreign currency and
acquisitions, was due to solid performance in most regions excluding
Germany. The Company has 6,100 associates and markets its
products in 80 countries around the world.

Spurred by the availability of improved analog formulations and
administration devices, demand for insulin and related delivery systems
will advance at a strong pace, increasing 9.2 percent annually through
2008.

dme lancets

This allows the caregiver to intervene when a patient
is non -compliant and may be at risk.

Despite the stronger sales growth, the
Company had a weak free cash flow quarter due to a company-wide build
in inventory and reduction in payables.
For the quarter, earnings before income taxes decreased to a loss of
$1. Even once the guidelines are finalized ,
there can be up to six months for implementation, and there will still
be uncertainty regarding CMS' plan to have 49 new codes and related
fees on power wheelchairs for 2006. This guidance anticipates foreign currency and acquisitions to
account for 13% of the net sales increase.

bidet nebulizers

In early 2007, the ALRT Home Monitoring system will also
have enhanced capabilities that will enable the monitoring of use and data
from medical diagnostic equipment such
as blood pressure and blood glucose monitors ."

(a) Free cash flow is a non-GAAP financial measure, which is
reconciled to the related GAAP financial measure in the
"Reconciliation" table included after the Condensed
Consolidated Balance Sheets in this press release.5 percent annually to $17.

nebulizer ridden

NORTH AMERICA

For the quarter , North American net sales increased 6% to $250.4 million versus $21. Terms such as "will," "should, " "plan,"
"intend," "expect," "continue," "forecast", "believe," "anticipate"
and "seek," as well as similar comments, are forward-looking in
nature.43 $0. Best opportunities are expected for
electrochemical blood glucose test strips and hemoglobin A1c diagnostic
devices.

syringes commode

ALRT500 Medication Compliance

The ALRT500, in conjunction with the Home Health Monitoring
System allows caregivers and healthcare providers to monitor the patient and
determine if the patient is taking medications or treatments at the
appropriate times.2 million for the first quarter
last year. Production in the quarter
was more evenly distributed during the quarter than during previous
periods, leading to a lower payables level for quarter end .

ASIA/PACIFIC

For the quarter, Asia/Pacific net sales increased 22% to $17. With the current
debt-to-total-capitalization level and the Company's recently expanded
revolving credit facility , the Company has the flexibility to continue
to make accretive acquisitions or to purchase common shares."
Mixon concluded, "The performance in the first quarter was
gratifying in the face of serious contractions in governmental health
care support.

uvb dme

com. Net sales for the quarter increased 15% to $370." Free cash
flow is defined as net cash provided (used) by operating activities
less purchases of property and equipment net of proceeds from sales of
property and equipment.7
million , bringing debt-to-total-capitalization to 42.). This
trend will boost demand for blood glucose monitors , test strips and lancets
in the home health care market and will broaden opportunities for
continuous monitoring systems and diabetes diagnostic products in the
primary health care sector., atherosclerosis , atrial hypertension, cholesterol
and obesity) will also strengthen growth opportunities for oral
anti-diabetic agents.

colostomy urostomy

The company has already received
an overwhelming response from healthcare providers, disease management companies
and private insurers and
expects to sell out entirely of the first production run before its third
quarter shipment. In
addition, reduced cost of care was demonstrated by a study conducted by
Missouri Medicaid. More information on ALR
Technologies and its products can be found at http://www. Further management discussions of risks and uncertainties can
be found in the company's' quarterly filings with the Securities Exchange
Commission. Results for the quarter benefited from higher
net sales and a stronger gross margin, which were partially offset by
higher selling, general and administrative expense (SG+A expense).
Respiratory products sales increased 16%, largely due to continued
strong performance on the HomeFill(TM) oxygen system product line and
strong sales of oxygen concentrators.
Sales of standard products decreased by 1% for the quarter, as the
benefit from increasing unit volumes of standard products was more
than offset by lower pricing. For the quarter,
earnings before income taxes increased to $3. Inventory turns were 4. Within the next two years, we
expect to increase the annual HomeFill(TM) sales by $100 million over
current levels.58. Secondly, Domus has again performed
strongly this quarter , and we are pleased with the contribution from
this recent acquisition. With the benefits from Chinese manufacturing, further
penetration of the ambulatory oxygen market with sales of the
HomeFill (TM) oxygen system, sales in the Far East and the Domus
acquisition, the Company now projects a 12 % to 20% growth in earnings
per share for 2005.

Invacare Corporation (NYSE:IVC), headquartered in Elyria, Ohio, is
the global leader in the manufacture and distribution of innovative
home and long-term care medical products that promote recovery and
active lifestyles. For more information about
the Company and its products, visit Invacare's website at
www.

PRESS RELEASE US Diabetes Monitoring Products +amp; Therapies Demand to Reach $17.6 Billion in 2008

commodes colostomy

html

About ALR Technologies, Inc.44 for the first quarter last year, while net earnings for the
quarter were $13.
Gross margin as a percentage of net sales for the first quarter
was higher by 0.1
million last year, due to the acquisition of Domus. The uncertainty negatively
affected the Company's first quarter results for consumer power
wheelchair sales, and will likely impact results all year. This
guidance anticipates foreign currency and acquisitions to account for
11% of the net sales increase .

Demand for blood glucose monitoring and diabetes diagnostic products is
projected to advance over 8 percent annually to $4.

ileostomy concentrators

This reminder system was designed for patients with chronic conditions such
as diabetes, heart disease, pulmonary disease, HIV, mental disorders, organ transplant, post surgery and severe asthma, or even those with less
severe problems but must be compliant with medications .42 versus
$0.9 million
versus $321. With increased shipments from
the Far East, the Company had more product in transit than in previous
years. Foreign currency accounted
for one percentage point of the net sales increase, while acquisitions
contributed an additional two percentage points for the quarter. Sales of consumer power wheelchairs were down 16% for the
quarter versus last year 's first quarter. Domus has
performed to expectation during the first quarter, while several of
the other Invacare Europe locations struggled to convert the sales
increase to profitable results.

OUTLOOK

Reimbursement uncertainties continue to affect the core North
American rehab and standard businesses. "The
HomeFill(TM) oxygen system product line has been one of the Company's
biggest successes and while it has become a major contributor to
growth, the opportunity for deeper penetration of the ambulatory
oxygen market remains substantial.
For the second quarter, the Company expects a net sales increase
of between 18% and 20% and earnings per share of between $0. We continue to believe that Domus is on track
with the projects to increase sales with Invacare Europe's sales
forces and to lower costs with Invacare's Hong Kong sourcing office
and Chinese manufacturing plants.

ridden dme

ALR
Technologies generates its revenue from the sale of the hardware as
well as monthly monitoring service fees, in addition to other product
sales. The ALRT
monitoring system is the only system that provides monitoring of nebulizer compressors, used
by COPD patients to
maintain health.

For more information on the ALRT500, please visit:
http://www. There are many factors that could cause
the actual results, performance or achievements of ALR Tech and its
products to be materially different from any future results, performances
or achievements that may be expressed or implied by such forward-looking
statements.
Additionally, WP Domus GmbH (Domus) had a higher gross margin than
that achieved historically by the Company. Inventory levels were temporarily inflated as the Company
consolidated previous Domus sales agencies, ramped up production in
its factories in China and worked through a major information systems
implementation in the Asia/Pacific region. Although the Centers for
Medicare and Medicaid Services (CMS) has released new draft guidelines
on power wheelchair eligibility, the guidelines have not been
finalized or implemented yet."
For the full year, the company believes that it will have a net
sales increase of between 17% and 19% and earnings per share of
between $2.

glucose holdaway

The directions are displayed on a screen on
the handheld sized device .9
million versus $237. The
reimbursement pressures did not significantly impact the Domus product
lines, and the Company anticipates improved revenue performance as it
finalizes the assimilation of the Domus agency business.

crutches lumbar

Products are now in use by patients
taking medications or treatments for conditions such as hypertension, high cholesterol, Parkinsons, diabetes, organ transplant, depression , anxiety, asthma, glaucoma and more. Despite the first quarter result, we expect the
company to generate strong free cash flow for the year. With market-driven pricing, the Company
is making progress from 2004 when the sales decline in the fourth
quarter in standard products was 8%.44
=========== ==========
Weighted average shares outstanding - assuming
dilution 32,534 32,272
=========== ==========

Business Segments - The Company operates in three primary business
segments based on geographical area: North America, Europe and
Asia/Pacific.